New hope for kids with rare blood disorders: benralizumab trial launches
NCT ID NCT06512883
First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 3 times
Summary
This Phase 3 trial tests the drug benralizumab (Fasenra) in children aged 6 to 17 with two rare eosinophilic diseases: EGPA and HES. The study aims to see if the drug is safe, how it works in the body, and whether it can help control the disease. Fourteen children will receive injections every 4 weeks, with researchers monitoring side effects and remission rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
benralizumab (Fasenra)
What this could lead to
If successful, this could provide a treatment option to control eosinophilic diseases in children, reducing symptoms and reliance on steroids.
What could go wrong
This is a small, open-label trial with only 14 participants, so results may not apply broadly. Side effects or lack of efficacy are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGAurora, Colorado, 80045, United States
-
Research Site
NOT_YET_RECRUITINGCincinnati, Ohio, 45229, United States
-
Research Site
RECRUITINGHighland Hills, Ohio, 44106-2624, United States
-
Research Site
RECRUITINGSão Paulo, 01232-010, Brazil
-
Research Site
RECRUITINGToronto, Ontario, M5G1X8, Canada
-
Research Site
NOT_YET_RECRUITINGLille, 59037, France
-
Research Site
NOT_YET_RECRUITINGMontpellier, 34295, France
-
Research Site
NOT_YET_RECRUITINGAhmedabad, 380052, India
-
Research Site
NOT_YET_RECRUITINGPetah Tikva, 49202, Israel
-
Research Site
RECRUITINGGuadalajara, 44620, Mexico
-
Research Site
NOT_YET_RECRUITINGRotterdam, 3015 GD, Netherlands
-
Research Site
NOT_YET_RECRUITINGKielce, 25-734, Poland
-
Research Site
NOT_YET_RECRUITINGWarsaw, 04-730, Poland
-
Research Site
RECRUITINGAltındağ, 06230, Turkey (Türkiye)
-
Research Site
RECRUITINGIstanbul, 34093, Turkey (Türkiye)